SLC5A2 and stroke disorder: Pooled analysis reported no significant effect on total stroke outcomes from treatment with SGLT2 inhibitors versus placebo (RR = 0.95, 95% CI 0.79–1.13, P = 0.585; Fig. 2], with mild effect heterogeneity across all studies (I2 = 43.7%, P for interaction = 0.150).